Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880219 | 0.84 | L3MBTL1 (0.50) | L3MBTL1IP6K1KDM4EACVR1TNF | |
| SCHEMBL7600132 | 0.81 | L3MBTL1 (0.60) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL29607244 | 0.81 | L3MBTL1 (0.60) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL4166506 | 0.80 | BRAF (0.64) | L3MBTL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4209022 | 0.80 | BRAF (0.45) | L3MBTL1IP6K1KDM4EACVR1TNF | |
| SCHEMBL30078199 | 0.80 | BRAF (0.45) | L3MBTL1IP6K1KDM4EACVR1TNF | |
| SCHEMBL422211 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL9919060 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL31723363 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL3230513 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | PFIZER INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12303509-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | PFIZER INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-4073044-B1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | HOFFMANN LA ROCHE (CH) | 2025-02-19 | — | — | EP | disclosed |
| US-20250011304-A1 | CRYSTALLINE FORM OF N-(2-CHLORO-3-((5-CHLORO-3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)AMINO)-4-FLUOROPHENYL)-3-FLUOROAZETIDINE-1-SULFONAMIDE | ARRAY BIOPHARMA INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-118369318-A | Crystalline forms of N- (2-chloro-3- ((5-chloro-3-methyl-4-oxo-3, 4-dihydroquinazolin-6-yl) amino) -4-fluorophenyl) -3-fluoroazetidine-1-sulfonamide | 阿雷生物药品公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-114746405-B | Novel BRAF inhibitors as anomalous breakers | 豪夫迈·罗氏有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4161907-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array BioPharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4073044-A1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | F. Hoffmann-La Roche AG (CH) | 2022-10-19 | — | — | EP | disclosed |
| US-20220298145-A1 | BRAF INHIBITORS AS PARADOX BREAKERS | HOFFMANN-LA ROCHE INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220288074-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| CN-114746405-A | Novel BRAF inhibitors as paradoxical breakers | 豪夫迈·罗氏有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021116050-A1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116050-A1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-17 | — | — | WO | disclosed |
| US-20090149484-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | L3MBTL1 311/4885IP6K1 1278/4885KDM4E 2362/4885 |
| US-20220288074-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | L3MBTL1 311/4885IP6K1 1278/4885KDM4E 2362/4885 |
| US-20220298145-A1 | BRAF INHIBITORS AS PARADOX BREAKERS | BRAF, NRAS, RAF1 | L3MBTL1 1107/4885IP6K1 526/4885KDM4E 1202/4885 |
| US-20250011304-A1 | CRYSTALLINE FORM OF N-(2-CHLORO-3-((5-CHLORO-3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)AMINO)-4-FLUOROPHENYL)-3-FLUOROAZETIDINE-1-SULFONAMIDE | BRAF, NRAS, KRAS | L3MBTL1 4213/4885IP6K1 1712/4885KDM4E 1231/4885 |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | L3MBTL1 1119/4885IP6K1 1534/4885KDM4E 1783/4885 |
| US-12303509-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | L3MBTL1 311/4885IP6K1 1278/4885KDM4E 2362/4885 |
| US-20090149484-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BRAF, RAF1, NRAS | L3MBTL1 4021/4885IP6K1 1421/4885KDM4E 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.